Antithrombotic therapy depicts a distinct small bowel bleeding clinical pattern: a retrospective cohort study
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S373
DOI: 10.1055/s-0044-1783620 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von C. Marmo und 6 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben.
Abstract (Originalsprache)
Aims
The study aims to evaluate the diagnostic yield of small bowel capsule endoscopy in patients while on antithrombotic therapy for suspected small bowel bleeding.
Methods
This is a single center, retrospective, observational study conducted from January 2015 to March 2019. We enrolled consecutive patients with suspected small bowel bleeding or iron deficiency anemia undergoing SBCE after bidirectional negative endoscopy. Positive findings were defined according to the P0-P2 classification reported by Saurin et al [ 1 ]. Bleeding severity was defined according to the "International Society of Thrombosis and Haemostasis" (ISTH) criteria. We considered in anticoagulant therapy: direct oral anticoagulant (DOAC), vitamin K antagonist (VKA), injective anticoagulant (Low-molecular-weight heparin, unfractionated heparin, fondaparinux). We considered in antiplatelet therapy: aspirin, clopidogrel, ticagrelor. A descriptive analysis of the data was performed, with a calculation of the mean, median, proportions, standard deviation and 95% confidence limits depending on data type.
Results
We analyzed and collected data from 369 patients, 95 while on antithrombotic therapy: 40 with DOACs, 35 with VKAs, and 20 with injective anticoagulants. The mean age was, overall, 66.4 years (SD±14.9), 60.1 years (SD±16.2) in the control group, 72.4 (SD±8.8) in the antiplatelet group, 73.3 years (SD±11.49) in the anticoagulant group and 71.3 years (SD±12.2) in the anticoagulant+antiplatelet group. In table 1, there are reported patients’ demographic and clinical characteristics. In the DOAC group we found a statistically significant higher number of patients presenting with active bleeding and without lesion identification (8 patients 20.0% Vs 11 patients 6.0% in the control group, 3 patients 8.6% in AVK group and 3 patients 15.0% in the injective anticoagulant group). The angioectasia is the most frequent lesion detected in patients with antiplatelet+anticoagulant therapy (7 patients 46.7% VS 21 patients 20.2% in the control group, 8 patients 21.1% in the antiplatelet group and 3 patients 8.8% in the anticoagulant alone group; p=0.027).
Conclusions
Our results show that patients with antithrombotic therapy are, usually, elderly and with more comorbidities than the control group. Furthermore, in this specific group, the hemoglobin level was lower and the need for transfusion was higher. Angioectasia is the most frequent positive findings in patients with both antiplatelet and anticoagulant therapy. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Marmo, C., Feliciani, D., Pola, R., Gaetani, E., Costamagna, G., Gasbarrini, A., & Riccioni, M. E. (2024). Antithrombotic therapy depicts a distinct small bowel bleeding clinical pattern: a retrospective cohort study. Endoscopy, 56(S 02 S 02), S373. https://doi.org/10.1055/s-0044-1783620
Vancouver
Marmo C, Feliciani D, Pola R, Gaetani E, Costamagna G, Gasbarrini A, et al. Antithrombotic therapy depicts a distinct small bowel bleeding clinical pattern: a retrospective cohort study. Endoscopy. 2024;56(S 02 S 02):S373. doi:10.1055/s-0044-1783620
BibTeX
@article{Marmo2024,
author = {Marmo, C. and Feliciani, D. and Pola, R. and Gaetani, E. and Costamagna, G. and Gasbarrini, A. and Riccioni, M. E.},
title = {Antithrombotic therapy depicts a distinct small bowel bleeding clinical pattern: a retrospective cohort study},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S373},
doi = {10.1055/s-0044-1783620}
}
EUVIMED